查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370502

卵巢癌市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Ovarian Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

概要

市場概況：

2022年全球卵巢癌市場規模達19億美元。展望未來，IMARC Group預計到2028年市場規模將達到37億美元，2023-2028年年複合成長率（CAGR）為11.56%。

卵巢癌是指由於脫氧核糖核酸（DNA）的誘變變化，卵巢中的異常細胞開始從外層組織襯裡或輸卵管不受控制地繁殖和生長的惡性腫瘤。目前，可以在多種診斷和藥物的支持下進行治療，包括抗風濕藥物、抗腫瘤藥物以及PARP、有絲分裂和VEGF/VEGFR抑制劑。除此之外，卵巢癌的治療還包括手術、化療、荷爾蒙、放射和標靶治療，這些治療有助於殺死癌細胞，從而緩解徵兆和系統症狀。這些療法是由醫生在確定多種因素後執行的，例如腫瘤的擴散、個人的整體健康狀況以及卵巢癌的大小和類型。

卵巢癌市場趨勢：

由於乳癌基因 1 (BRCA1) 或 BRCA2 的基因突變，上皮癌、間質癌和生殖細胞卵巢癌的盛行率不斷增加，特別是在女性老年族群中，這主要推動了市場的成長。與此一致的是，對貝伐單抗（Avastin）和帕唑帕尼（Votrient）等有效治療藥物的需求不斷成長，成為另一個生長誘導因素。此外，醫療保健領域廣泛採用聯合療法來防止抗藥性和提高治療效果，這也支持了市場的成長。此外，品牌藥物的專利持續到期促使政府和製藥公司推出新型重組藥物，這反過來又推動了市場成長。此外，非政府組織 (NGO) 為提高消費者對早期卵巢癌診斷的症狀、治療和益處的認知而採取的廣泛舉措正在推動市場成長。除此之外，主要參與者之間的策略合作以及持續的研發（R＆D）活動以產生有效的治療干涉措施，正在為市場創造積極的前景。

本報告回答的關鍵問題：

  • 迄今為止，全球卵巢癌市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球卵巢癌市場有何影響？
  • 主要區域市場有哪些？
  • 依類型分類市場是怎麼樣的？
  • 根據治療類型的市場分類是怎樣的？
  • 基於最終用戶的市場區隔是什麼？
  • 產業價值鏈的各個階段是什麼？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球卵巢癌市場的結構如何？誰是主要參與者？
  • 產業競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球卵巢癌市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：按類型分類的市場細分

  • 上皮性卵巢癌
    • 市場走向
    • 市場預測
  • 生殖細胞卵巢癌
    • 市場走向
    • 市場預測
  • 基質細胞卵巢癌
    • 市場走向
    • 市場預測

第 7 章：按治療類型分類的市場區隔

  • 免疫療法
    • 市場走向
    • 市場預測
  • 化療
    • 市場走向
    • 市場預測
  • 標靶治療
    • 市場走向
    • 市場預測
  • 手術
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：最終用戶的市場區隔

  • 醫院
    • 市場走向
    • 市場預測
  • 居家護理
    • 市場走向
    • 市場預測
  • 專科中心
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場區隔

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112023A6407

Abstract

Market Overview:

The global ovarian cancer market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 11.56% during 2023-2028.

Ovarian cancer refers to a malignant tumor wherein abnormal cells in the ovary begin to multiply and grow uncontrollably from the outer tissue lining or fallopian tubes due to mutagenic changes in the deoxyribonucleic acid (DNA). At present, it can be treated with the support of various diagnoses and drugs, including antirheumatics, antineoplastics, and PARP, mitotic, and VEGF/VEGFR inhibitors. Apart from this, ovarian cancer treatment involves surgery, chemotherapy, hormone, radiation, and targeted therapies that help kill cancer cells to provide relief from signs and systems. These therapeutics are executed by medical practitioners after determining multiple factors, such as the spread of the tumor, individuals' general health, and the size and type of ovarian cancer.

Ovarian Cancer Market Trends:

The increasing prevalence of epithelial, stromal, and germ cell ovarian cancer, especially amongst the female geriatric population, due to the genetic mutation of breast cancer gene 1 (BRCA1) or BRCA2, is primarily driving the market growth. In line with this, the rising need for effective therapeutic drugs, such as bevacizumab (Avastin) and pazopanib (Votrient), is acting as another growth-inducing factor. Additionally, the widespread adoption of combination therapies in the healthcare sector to prevent drug resistance and increase treatment efficacy is supporting the market growth. Moreover, the ongoing patent expiration of branded medications has prompted governments and pharmaceutical companies to launch novel recombinant drugs, which, in turn, is propelling market growth. Furthermore, extensive initiatives undertaken by non-governmental organizations (NGOs) to sensitize consumers regarding the symptoms, treatments, and benefits of early ovarian cancer diagnosis are impelling the market growth. Apart from this, strategic collaborations amongst key players and continuous research and development (R&D) activities to produce efficient therapeutic interventions are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ovarian cancer market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

Epithelial Ovarian Cancer

Germ Cell Ovarian Cancer

Stromal Cell Ovarian Cancer

Breakup by Treatment Type:

Immunotherapy

Chemotherapy

Targeted Therapy

Surgery

Others

Breakup by End User:

Hospitals

Homecare

Speciality Centre

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global ovarian cancer market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ovarian cancer market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global ovarian cancer market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2022
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2022
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million US$), 2023-2028
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players